Video
JPM Week 2024: Addressing the Latest Market Drivers and Trends for Biologics and Sterile Injectables
Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.
View Now
White Papers
Improving Methodologies for iPSC Manufacturing & Differentiation
Learn about pluripotent stem cells and how they're being explored as an exciting alternative gene therapy technology with the potential to transform the field of
regenerative medicine.
View Now
White Papers
Bridging the Gap Between Promise and Practicality: Cell and Gene Therapy Advancements, Challenges, and the Path to Commercial Success
In recent years, the field of gene therapy has witnessed remarkable achievements and advancements. These breakthroughs have brought us even closer to unleashing the full potential of gene therapies. Catalent gene therapy experts discuss all aspects of gene therapy commercialization in depth.
View Now
Poster
Poster: GMP Compliant iPSC Lines and Immune-Oncology Platform for Allogeneic Cell Therapy
A poster presentation of a GMP manufacturing process for the creation of human iPSC for use in allogeneic cell therapy applications.
View Now
Poster
Poster: Fully Closed, Scaled, Automated Analytics-on-Boarded GMP Compliant CAR-T Platform
A poster presentation of the UpTempo CAR-T Manufacturing Platform.
View Now
Webinars
CGMP-Compliant iPSC Manufacturing and Development of Differentiated Cells for Advanced Therapies: Strategies and Challenges
In this webinar, experts discuss the current state-of-the-art for iPSC generation and differentiation. The presentation will also highlight the development of advanced CGMP-compatible protocols for converting these cells into several cell types of therapeutic relevance, including retinal pigment epithelium (RPE), mesenchymal stem cells (MSCs), cardiomyocytes (CMs), and immune natural killer (NK) cells.
View Now
Article
The Current State of the Cell Therapy Market: Q&A with Maria Lopez, General Manager, US Cell Therapy at Catalent Biologics
Catalent’s Maria Lopez, General Manager of US Cell Therapy discusses the current state of the cell therapy market and the ways Catalent is working to overcome some of these challenges. Based on an interview conducted by, and published in, BioBuzz.
View Now
Webinars
GMP Process for High-Quality iPSC Manufacturing and Development of Improved Differentiation Methodologies
In this webinar, experts will discuss the evolution of protocols associated with induced pluripotent stem cell generation and differentiation.
View Now
Executive Summary
Early Phase Support for Plasmid DNA Supply to Secure Future Manufacturing
Summary: One significant challenge in the manufacturing of cell and gene therapies is the production of high quality plasmid DNA (pDNA). pDNA is a critical raw material for advanced therapeutics including mRNA and viral vector-based cell and gene therapies and vaccines.
View Now
Video
Catalent’s iPSCs as a Starting Material for Advanced Cell Therapies
Summary: iPSCs are a critical starting material for advanced cell therapies. Learn more about Catalent’s GMP iPSC capabilities including reprogramming, differentiation, and cell banking, and how they can advance cell therapies to clinic.
View Now